mark james litton  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors mark james litton check out list of companies and businesses related to mark james litton find out mark james litton address and contact details view other people related to mark james litton  coworkers colleagues companions etc address  north creek parkway south bothell  wa companies related to mark james litton cikcompany namepositioncompany addressalder biopharmaceuticals incchief business officer  north creek parkway south bothell  mark james litton on the web persons related to mark james litton  alder biopharmaceuticals incnamepositioncityjon w baylessdallasjon w baylessdallaslarry benedictevp and pao bothellpeter bisgaardbothelljames j bochnowskimenlo parkdavid bondermanfort worthdavid bondermanfort worthgary bridgerdirector vancouvergary bridgervancouverjames b buchersr vp  general counsel bothellpaul rutherford carterdirector uxbridge middlesexpaul b clevelanddirector palo altojames g coulterfort worthjames g coulterfort worthaaron davidsondirector miamidelphi bioinvestments vii lpmenlo parkdelphi management partners vii llc owner menlo parkdelphi ventures vii l pmenlo parkstephen l domenikdallasstephen l domenikdallasdavid l douglassmenlo parkstephen m dowdirector dallasstephen m dowdirector dallashig venture partners ii lp owner miamihig ventures  alder llcmiamirandal hasslersvp pharmaceutical ops bothelljohn v jaggers owner dallasjohn v jaggers owner dallasjackie r kimzeydallasjackie r kimzeydallasjohn a lathamchief scientific officer bothellmark james littonchief business officer bothelldavid j mcleandallasalan bruce montgomerydirector foster cityalan bruce montgomerydirector bothellas novo owner hellerupjohn t oxaaldallasdeepika pakianathandirector palo altodeepika pakianathandirector menlo parkheather prestondirector fort worthdouglas a roedermenlo parkelisabeth sandovalchief commercial officer westlake villagerandall c schatzmanpresident and ceo bothellalan r schueledallasalan r schueledallassevin rosen fund ix lpdallassevin rosen ix affiliates fund lpdallasclay b siegalldirector bothellclay b siegalldirector bothelljeffrey t l smithsr vp translational medicine bothellsrb associates ix lp owner dallasnicholas g sturialedallasnicholas g sturialedallastpg group holdings sbs advisors inc owner fort worthtpg group holdings sbs advisors incfort worthwest  limited partnership ventures owner vancouvertimothy m whitakerchief medical officer bothellwendy l yarnodirector st paul potentially same personnamecitycountryjames markbroomfieldcojames markportlandor about — litton entertainment menu  litton entertainment is a leading producer and distributor of awardwinning content that entertains and inspires hundreds of millions globally  litton team members and production studios are located throughout the united states making litton uniquely positioned to create and leverage programming across multiple platforms see the latest news on litton herelitton entertainment produces over  hours of emmy awardwinning programming on leading broadcast networks including abc cbs nbc and the cw including “litton’s weekend adventure” seen nationally on abc stations “cbs dream team it’s epic” and “one magnificent morning” airing saturday mornings on the cw litton also provides nbc stations six original ei series under the iconic brand the more you know additionally litton syndicates a variety of entertainment and news programs to over  television stations in the united states and the company’s diverse portfolio of programs air in  countries worldwide including the new ei block go time and consumer reports tv litton entertainment has received numerous national awards for outstanding achievement in television programming including  emmy awards  parents choice awards and  telly awards a coveted honor from one of americas most prestigious organizations dedicated to promoting the highest quality programminglitton is majorityowned by hearst httpwwwhearstcom  litton’s diverse team of experts brings indepth knowledge and transformative thinking to litton’s content development and partnership relationsdave morgan is the founder president and chief executive officer of litton entertainment mr morgan has built litton entertainment into one of the country’s largest privately held independent television programming companies working with partners including disney abc nbc universal and pepsi prior to founding litton entertainment in  dave morgan held executive management positions with hearst radio taft broadcasting and katz televisionpete sniderman litton’s chief operating officer has overseen the company’s expansion and growth through his leadership of several divisions including corporate and advertising sales partnerships international sales programming acquisitions network partnerships and the creation of littons news division litton news source in addition sniderman also leads the companys innovative public service platforms as well as littons international sales and marketing initiativeslisa jones executive assistant to the ceo assists and maintains schedules and calendars for the ceo and coodan solomon managing director leads the business development team and is responsible for initiatives with brands and nonprofit institutions as well as digital distribution initiatives across interactive television social web and mobile platformsmeg lavigne president of television leads litton’s syndicated entertainment and news content division and is responsible for the company’s public relations communications and creative services strategy in collaboration with litton’s network and television station partnersdavid doyle evp production  development oversees the company’s original production  development departments manages relationships with talent agents and the production community  supervises all production personnel and operations for the company’s current programming slate out of litton’s burbank ca officesbryan curb executive producer oversees production and postproduction for multiple litton projectsmark rains executive in charge of production oversees the company’s production management personnel as well as financial and logistical operations for the company’s current programming slate out of litton’s burbank ca officesmark cooper evp domestic distribution is responsible for creating and managing relationships with television stations corporate station groups and other media outlets as well as creating new business upgrading existing accounts and contributing to the research and development of new contentdonna wall director affiliate relations and operations of television syndication is responsible for administrative organization of the tv division and station affiliate liaison for all tv station partnerssterling eason senior director business development manages third party production partnerships business development activities with corporate partners and guides sponsorship execution for brands and nonprofit institutionsamy degregorio senior director integrated marketing manages business development and strategic marketing programs for brands and nonprofit institutions across littons programming portfolio laura pramstaller associate director of business development and marketing assists and executes business development and marketing activities for sponsorship executioncaitlin yaniec business development and marketing associate assists and executes business development and marketing activities for sponsorship executionilana gordon senior producer branded content manages endtoend relationships with branded content partners and serves as liaison with production to ensure proper execution of all contracted branded initiatives develops branded content and integrations in conjunction with the company’s sponsorship sales development and production teams sara krajewski public relations and affiliate relations director develops and executes all internal and external communications and public relations strategies for all platforms with existing partners and television affiliatescourtney parnell director of business affairs manages daily operations for the company’s business objectives and the content approval process across litton’s multiple platforms in addition she works closely with production partners and network executives to ensure compliance with contractual and legal obligationsjames shuler business affairs operations associate assists with operations network compliance and legal mattershannah reynolds business affairs associate assists with content approval network compliance and business operations ashley deschamps business affairs associate assists with contracts content approval network compliance and business operations andrew tew director of digital initiatives and distribution works in partnership with digital platforms as well as manages the identification execution and communication of litton’s digital strategy collaborates with the business development and business affairs teams as well as strategy and execution of clientspecific campaignsjustin aranda social media manager produces manages and distributes content that reflects littons prosocial mission through various social media platforms conceptualizes and implements social media strategies that leverage the power of conversation and spike interest in television programminghaley clarke digitalsocial media associate assists in management and distribution of showbased content through various social media platforms collaborates with production staff and program partners to develop robust social audiences while supporting various marketing and messaging objectives roger ovalle digital content producer responsible for gathering of creative content for litton entertainments various social media platforms adam sumner post production supervisor directs the post production process as well as communication between producers editors and sounds mixers to deliver the product for network broadcastdavid hill director creative services leads litton’s media creative strategy including producing onair promos for all network time periods sizzle reels for litton’s expansive show library and network promotional video requests for all networks carrying litton programmingjason davis art director leads all inhouse design efforts illustration and creative for litton entertainmentclifton mcdaniel assistant director creative services creates reels and onair promos as well as conversion of broadcast shows for digital distributioneileen mills accountant manages accounts payable lynell baldwin production accountant manages the production accounting for littons scripted programmingjessica smith human resource manager manages all aspects of personnel including recruiting hiring payroll and benefits laura hays senior production manager oversees all organizational scheduling and budgetary operations for the companys current programming slate out of littons burbank ca offices to reach litton team members please contact us here alder biopharmaceuticals inc aldro people  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states alder biopharmaceuticals inc aldro related topics stocksstock screenermarket datahealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse aldro on consolidated issue listed on nasdaq global market usd  jul  change  chg   prev close 9 open  days high  days low  volume 9 avg vol  wk high  wk low  summary name age since current position stephen dow   independent chairman of the board randall schatzman   president chief executive officer director larry benedict   executive vice president principal accounting officer james bucher   senior vice president general counsel randal hassler   senior vice president  pharmaceutical operations john latham  chief scientific officer mark litton  chief business officer treasurer and secretary elisabeth sandoval   chief commercial officer jeffrey smith   managing director of alder biopharmaceuticals limited timothy whitaker   chief medical officer paul carter   independent director paul cleveland   independent director a bruce montgomery   independent director deepa pakianathan   independent director heather preston   independent director clay siegall   independent director wendy yarno   independent director » insider trading biographies name description stephen dow mr stephen m dow is independent chairman of the board of the company mr dow has served as a general partner with sevin rosen funds a venture capital firm since 9 during his time with sevin rosen funds mr dow has served as a director on numerous boards of directors both public and private mr dow previously served on the board of directors of citrix systems inc from  to  and cytokinetics inc from  to  mr dow holds an mba and a ba in economics from stanford university randall schatzman dr randall c schatzman phd is president chief executive officer director of the company dr schatzman served as senior vice president of discovery research at celltech rd inc a whollyowned subsidiary of celltech group plc a biopharmaceutical company where he led a group of scientists responsible for much of the therapeutic antibody pipeline for celltech from 9 to 9 dr schatzman served as director of gene discovery at mercator genetics inc a genomics company from  to 9 dr schatzman served as section leader at roche bioscience previously syntex corp a subsidiary of roche holdings ltd a biotechnology company where he helped found the cancer and developmental biology institute dr schatzman holds a phd in molecular pharmacology from emory university and a bs in biochemistry from purdue university larry benedict mr larry k benedict is executive vice president principal accounting officer of the company he served as our senior vice president of finance from january  to october  and as our vice president of finance from june  to january  from  to  mr benedict served in various positions at seattle genetics inc a publiclytraded biotechnology company most recently as director of finance and controller mr benedict holds a bs in accounting from central washington university james bucher mr james b bucher jd is senior vice president general counsel of the company mr bucher served as a consultant providing legal services to several life sciences companies from  to  mr bucher served as vice president corporate legal affairs and secretary and as the corporate compliance officer of exelixis inc a biopharmaceutical company from  to  mr bucher practiced as a corporate attorney at the international law firm shearman  sterling llp becoming a partner in  mr bucher holds a jd with distinction from emory university school of law and a ba in biology from colgate university randal hassler mr randal a hassler is senior vice president  pharmaceutical operations of the company mr hassler served in various leadership positions at seattle biomedical research institute a nonprofit infectious disease research institute most recently as chief operating officer from 9 to  he served in various leadership positions at amgen inc a biopharmaceutical company including process development quality control and quality assurance from 9 to 9 mr hassler served in a variety of research and development positions at synergen inc a biotechnology company which was acquired by amgen in  mr hassler holds a bs in microbiology from indiana university and an ms in microbiology from colorado state university john latham dr john a latham phd is chief scientific officer of the company dr latham served as a director senior director and most recently as vice president of gene function and target validation for celltech group plc in  dr latham joined darwin molecular corporation a firstgeneration genetodrug biotechnology company as a founding director where he served from  to  dr latham was one of the early scientists hired by gilead sciences inc a biopharmaceutical company and from  to  he was a member of a core group established to exploit novel oligonucleotidebased technologies dr latham holds a phd in biochemistry from massachusetts institute of technology and a bs in chemistry from colorado state university mark litton dr mark james litton phd is chief business officer treasurer and secretary of the company dr litton served as vice president of business development for celltech group where he was responsible for securing commercializing and partnering numerous novel discoveries and therapeutic opportunities in 9 dr litton joined celltech group as an employee of chiroscience group plc and was later promoted to vice president business development after chiroscience’s merger with celltech group in 9 from 9 to 9 dr litton served as the manager of business development for ribozyme pharmaceuticals inc currently sirna therapeutics inc a biopharmaceutical company and whollyowned subsidiary of alnylam pharmaceuticals inc where he helped form relationships with eli lilly and company roche bioscience and glaxowellcome plc currently glaxosmithkline plc a biopharmaceutical company from  to  dr litton served as a research associate for dnax research institute a research facility of scheringplough now merck  co a publiclytraded pharmaceutical company dr litton holds a phd in immunology from stockholm university an mba from santa clara university and a bs in biochemistry from the university of california santa cruz elisabeth sandoval ms elisabeth a sandoval is chief commercial officer of the company ms sandoval has served as our chief commercial officer since august  from march  to october  ms sandoval served as the chief commercial officer for kythera biopharmaceuticals inc a biopharmaceutical company from  to  she served as vice president of global marketing and strategy at bausch  lomb incorporated an eye health product company from 9 to  she held various roles at allergan plc including global vice president strategic marketing and senior director of global strategic marketing which included sales management and marketing leadership for multiple products including botox for neurological and other disorders she began her career in research and development at johnson  johnson’s ethicon division ms sandoval holds an mba from pepperdine university and a bs in biology from the university of california irvine jeffrey smith dr jeffrey tl smith md is managing director of alder biopharmaceuticals limited a subsidiary of the company dr smith previously served as our senior vice president translational medicine from  to march  and in other senior management positions from april  to  from 9 to  dr smith served as senior director of medical research for celltech rd where he was responsible for planning and managing the cdp antitnf clinical trials for ra as well as several other key autoimmune clinical development programs from 9 to 9 dr smith served as medical director at simbec research ltd a contract research organization from 9 to 9 dr smith served as head of clinical pharmacology at hoechst marion roussel ltd a pharmaceutical company from  to 9 dr smith served as a senior clinical physician at the proctor and gamble company a publiclytraded consumer products company and from  to  he served as a senior research physician in the clinical pharmacology department at glaxo research and development ltd now a division of glaxosmithkline plc a healthcare company dr smith holds an md from the university of london and is a fellow of the royal college of physicians in london timothy whitaker dr timothy m whitaker md is chief medical officer of the company dr whitaker has served as our chief medical officer since june  from  to december  dr whitaker held various positions at shire plc most recently as the vice president and neuroscience therapeutic area head of global clinical development from  to  dr whitaker held the positions of associate director director and senior director of clinical research and development for the neuroscience divisions at wyeth pharmaceuticals from 9 to  he held a variety of teaching and clinical appointments at the university of vermont college of medicine and the medical center hospital of vermont including associate professor of psychiatry and director of the psychopharmacology clinic dr whitaker holds an md from wake forest university school of medicine in winstonsalem nc and a ba from duke university paul carter mr paul rutherford carter is independent director of the company mr carter served in various roles at gilead sciences inc a research based biopharmaceutical company most recently serving as executive vice president commercial operations prior to joining gilead mr carter spent  years in the pharmaceutical industry with glaxosmithkline and its legacy companies during his time with glaxosmithkline mr carter gained increasing levels of senior experience as general manager in europe and later as a regional head of the international business in asia mr carter currently serves on the board of directors of hutchison china meditech ltd a biopharmaceutical company mr carter holds a degree in business studies from the ealing school of business and management now merged into university of west london and is a fellow of the united kingdom’s chartered institute of management accountants paul cleveland mr paul b cleveland is independent director of the company mr cleveland has served as the executive chairman of the board of directors of adverum biotechnologies inc a biotechnology company from december  to october  mr cleveland served as president and chief executive officer of adverum from may  to november  mr cleveland served as president and chief executive officer at celladon corporation a clinicalstage biotechnology company and previously served as celladon’s president and chief financial officer since june  from february  to august  mr cleveland served as executive vice president corporate strategy and chief financial officer of aragon pharmaceuticals inc a biotechnology company from april  to february  mr cleveland served as general partner and chief operating officer of mohr davidow ventures a venture capital firm from january  to february  mr cleveland served as executive vice president corporate development and chief financial officer of affymax inc a biopharmaceutical company from april  to december  he served as a managing director at integrated finance ltd an investment bank from september  to april  mr cleveland served as a managing director at investment bank jp morgan chase and co and a predecessor firm hambrecht  quist from january  to september  mr cleveland was a partner at cooley llp from december 9 to december  he was a corporate attorney at sidley austin llp and from september 9 to november 9 he was a corporate attorney at davis polk  wardwell llp mr cleveland currently serves as the executive chairman of the board of directors of adverum biotechnologies mr cleveland previously served on the board of directors of sangamo biosciences inc from november  to august  and on the board of directors of celladon from may  to november  a bruce montgomery dr a bruce montgomery md is independent director of the company dr montgomery has served as the chief executive officer of genoa pharmaceuticals inc a pharmaceutical company in  dr montgomery founded cardeas pharma corporation a biotechnology company where he served as chief executive officer and a member of the board of directors from  to december  in  he founded corus pharma inc a biotechnology company and served as its chief executive officer from  through its acquisition in  by gilead sciences inc he continued on at gilead postacquisition until  and served as senior vice president and head of respiratory therapeutics where he successfully led the approval of cayston aztreonam as a treatment for cystic fibrosis patients from  to  dr montgomery held positions within the research and development group of pathogenesis corporation a biotechnology company from  to  dr montgomery worked at genentech inc a biotechnology company dr montgomery currently serves on the board of directors of cytodyn inc and xencor inc dr montgomery holds an md and a bs in chemistry from the university of washington deepa pakianathan dr deepa r pakianathan phd is independent director of the company dr pakianathan has been a managing member at delphi ventures a venture capital firm focused on biotechnology and medical device investments and leads the firm’s biotechnology investment activities from  to  dr pakianathan was a senior biotechnology banker at jpmorgan a global investment bank from 9 to  she was a research analyst covering biotech at genesis merchant group and from  to 9 she was a postdoctoral research scientist at genentech dr pakianathan serves on the boards of directors of karyopharm therapeutics inc a biopharmaceutical company where she serves as a member of its audit and compensation committees oncomed pharmaceuticals inc a biopharmaceutical company where she serves as a member of its audit and compensation committees and calithera biosciences inc a biopharmaceutical company where she serves as a member of its audit and nominating and governance committees from  to  dr pakianathan served on the board of directors of alexza pharmaceuticals inc from 9 to february  dr pakianathan served on the board of directors of ptc therapeutics inc and from  to  dr pakianathan served on the board of directors of relypsa inc each a biopharmaceutical company dr pakianathan received a bsc from the university of bombay india a msc from the cancer research institute at the university of bombay india and an ms and phd from wake forest university heather preston dr heather preston md is independent director of the company dr preston has served as a managing director at tpg biotech a biotechnology venture capital firm prior to joining tpg biotech dr preston served for two years as a medical device and biotechnology venture capital investor at jp morgan partners llc a private equity firm prior to that she was an entrepreneurinresidence at new enterprise associates a venture capital firm from 9 to  dr preston served as a leader of the pharmaceutical and medical products consulting practice at mckinsey  co in new york dr preston currently serves on the board of directors of otonomy inc and on numerous private company boards of directors dr preston holds an md from the university of oxford and a bs in biochemistry from the university of london clay siegall dr clay b siegall phd is independent director of the company dr siegall cofounded seattle genetics inc a biotechnology company and currently serves as its president chief executive officer and chairman of the board of directors from  to 9 dr siegall was with the bristolmyers squibb pharmaceutical research institute and the national cancer institute national institutes of health from 9 to  in addition to seattle genetics and alder dr siegall currently serves on the board of directors of ultragenyx pharmaceutical inc and he previously served on the board of directors of mirna therapeutics inc from january  to december  dr siegall holds a phd in genetics from george washington university and a bs in zoology from the university of maryland wendy yarno ms wendy l yarno is independent director of the company ms yarno retired in september  from merck  co inc following a year career there in commercial and human resource positions of increasing seniority most recently chief marketing officer before she retired prior to this role she served as general manager cardiovascularmetabolic united states business unit where she had pl responsibility for merck’s largest therapeutic area and as senior vice president human resources from september  through september  ms yarno was the chief marketing officer of hemoshear llc a biotechnology research company and leading developer of human cellbased surrogate systems for discovery and assessment of new drug compounds ms yarno currently serves on the board of directors of myokardia inc a biopharmaceutical company and aratana therapeutics inc a pet therapeutics company ms yarno previously served as member of the board of directors of st jude medical inc a medical device company from april  until january  when st jude medical was acquired by abbott laboratories medivation inc a biopharmaceutical company from april  until september  when medivation was acquired by pfizer inc and durata therapeutics inc a pharmaceutical company from august  until november  when durata was acquired by actavis plc ms yarno holds a bs in business administration from portland state university and an mba from temple university basic compensation name fiscal year total stephen dow  randall schatzman  larry benedict 9 james bucher  randal hassler  john latham  mark litton  elisabeth sandoval  jeffrey smith  timothy whitaker  paul carter  paul cleveland 9 a bruce montgomery  deepa pakianathan  heather preston 9 clay siegall  wendy yarno  as of   dec  options compensation name options value stephen dow   randall schatzman   larry benedict   james bucher   randal hassler   john latham   mark litton   elisabeth sandoval   jeffrey smith 9 9 timothy whitaker   paul carter   paul cleveland   a bruce montgomery   deepa pakianathan   heather preston   clay siegall   wendy yarno   insider trading name shares traded price yarno wendy l   dow stephen m   smith jeffrey t l   smith jeffrey t l   schatzman randall c   schatzman randall c   litton mark james phd   litton mark james phd   litton mark james phd   litton mark james phd   litton mark james phd   litton mark james phd   litton mark james phd   litton mark james phd   litton mark james phd   latham john a   latham john a   latham john a   smith jeffrey t l   smith jeffrey t l   smith jeffrey t l   schatzman randall c   benedict larry k   latham john a   latham john a   » full list on insider trading related topics stocksstock screenermarket datahealthcarebiotechnology  medical research litton mark james top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active litton mark james • bothell wa how do i update this listing litton mark james is based out of bothell summary dg insider form  create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from litton mark james enter your email address below and choose submit your email cancel contact info litton mark james  north creek parkway south bothell wa     recent sec filings  filed on   filed on   filed on 9  filed on 9  filed on   filed on   filed on   filed on   filed on   filed on  schedule d and g events since  subscription required form   nonderivative insider transactions since  loading elevate your investments try it for free mark litton  alder biopharmaceuticals inc  zoominfocommr mark litten james healthcare services group limited  director profile  information  duedil search for a company or director sign insign inproductteamscustomersplansaboutinternationalbloghelptalk to sales    product teams customers plans about contact duedil mr mark litten jamesadd to listkey informationdirectorshipsnewsmapactive directorshipsclosed directorshipsretired directorshipsnationalitybritishmr mark litten jamess profile director of healthcare services group limited born available to duedil premium and enterprise customers  start a free trial nationality british about mr mark litten james is british the first directorship we have on file for him was in 9 at aah pharmaceuticals limited his newest directorship is with ommovianto uk holdings ltd where he holds the position of none the company was established  aug  so far mark has held  directorships  of which are currently active and  are no longer activerelated directorsofficer withatdave smithwidgets  things uk ltdian davieswidgets  things uk ltdnick downiewidgets  things uk ltdrelated directorsfind existing and previous codirectorssee samplesocial mediaadd twitter account add a facebook page add a linkedin profile possible matches owen brandon director at widgets r not usfull name and date of birth match owen smith director at fantastic widgets limitedforename and date of birth matchpossible matchessometimes names are entered inconsistently find other directors with matching names and dates of birthsee sample find the decision makers at any company build lists across any market segment find the relevant contacts and get in touch with ease make your business more agile and resilient todayview planslearn moregrow revenuestreamline onboardingminimise riskimprove collaboration× what is a markup on a product  chroncom skip to main content what is a markup on a product by m scilly a product markup can be represented as a percent hemera technologiesphotoobjectsnetgetty images related articles  excel functions for adding a percentage markup  how to calculate markup cost  how to do percent markup in excel  how to add a markup percent to a product if youre in the retail business youve likely heard mention of product markups product markups are a means of pricing products based on their costs calculate the markup as a percent or as a dollar value to see what your markup is and use a predetermined markup percentage to set your own prices markup in dollars when markup is expressed in dollars it is simply the difference between the cost to acquire a product and the price that you can sell it for assume for example that you purchase a product for  and sell it for  to calculate the markup in dollars you would simply subtract the  cost from the  selling price giving you a markup of  markup as a percentage markup can also be expressed as a percentage you need to divide the sale price by the cost and then subtract  to calculate markup as a percentage assume once again that you have a product that costs  for you to purchase and that you sell it for  to calculate the markup as a percentage divide  by  to get  and subtract  to get  or  percent using markup pricing markup pricing can be a simple way to ensure that your products make a certain profit if they sell to calculate a price using a markup simply multiply the cost of the product by the desired markup percentage and add the total to the products sales cost for example if you have a product that costs  and you want to mark it up by  percent multiply  by  percent to get  and then add  to  to get a  sales price determining your markup there is no hard and fast way to determine the appropriate markup for a product in general you should choose a markup that is in line with competitors in your industry for instance if the typical markup in your industry is between  and  percent you might select  percent as your markup always take into account how that will affect your sales price however and adjust it if your price is too high or low based on demand for your product references  entrepreneur demystifying profit margins and markupsmanagerial economics mark hirschey about the author m scilly is a writer and editor who writes for various online publications specializing in business and management he has a fondness for travel and photography in his free time he enjoys marathon training photo credits hemera technologiesphotoobjectsnetgetty images suggest an article correction related searches more articles what is a normal markup percentage how to work out markup percentages calculation of a fuel surcharge how to calculate gross profit margin percentage also viewed standard markup in the shoe industry what is a good markup percentage in the candy industry how to calculate the cost of goods how to create a liquor inventory  costing spreadsheet how to add a share button to a facebook fan page what is a pricing margin what is a good markup price for a shirt